A 1120
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558768

CAS#: 1152782-19-8

Description: A 1120 is a retinol-binding protein 4 (RBP4) antagonist (Ki = 8.3 nM) that can reduce serum RBP4 and retinol, and displaces transthyretin (TTR) from RBP4-TTR complexes.

Chemical Structure

img
A 1120
CAS# 1152782-19-8
Instruction

Theoretical Analysis

MedKoo Cat#: 558768
Name: A 1120
CAS#: 1152782-19-8
Chemical Formula: C20H19F3N2O3
Exact Mass: 392.13
Molecular Weight: 392.378
Elemental Analysis: C, 61.22; H, 4.88; F, 14.53; N, 7.14; O, 12.23

Price and Availability

Size Price Availability Quantity
10mg USD 520 2 Weeks
50mg USD 1350 2 Weeks
Bulk inquiry

Synonym: A-1120, A1120, 2-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid

IUPAC/Chemical Name: 2-(4-(2-(Trifluoromethyl)phenyl)piperidine-1-carboxamido)benzoic acid

InChi Key: MEAQCLPMSVEOQF-UHFFFAOYSA-N

InChi Code:

SMILES Code: O=C(NC3=C(C(O)=O)C=CC=C3)N1CCC(C2=C(C(F)(F)F)C=CC=C2)CC1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 392.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x


1: Dobri N, Qin Q, Kong J, Yamamoto K, Liu Z, Moiseyev G, Ma JX, Allikmets R, Sparrow JR, Petrukhin K. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis. Invest Ophthalmol Vis Sci. 2013 Jan 7;54(1):85-95. doi: 10.1167/iovs.12-10050. PMID: 23211825; PMCID: PMC3544424.


2: Vajpai S, Taylor PE, Adholeya A, Leigh Ackland M. Chromium tolerance and accumulation in Aspergillus flavus isolated from tannery effluent. J Basic Microbiol. 2020 Jan;60(1):58-71. doi: 10.1002/jobm.201900389. Epub 2019 Oct 16. PMID: 31617602.


3: Hussain RM, Ciulla TA, Berrocal AM, Gregori NZ, Flynn HW Jr, Lam BL. Stargardt macular dystrophy and evolving therapies. Expert Opin Biol Ther. 2018 Oct;18(10):1049-1059. doi: 10.1080/14712598.2018.1513486. Epub 2018 Sep 10. PMID: 30129371.


4: Lu LJ, Liu J, Adelman RA. Novel therapeutics for Stargardt disease. Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1057-1062. doi: 10.1007/s00417-017-3619-8. Epub 2017 Mar 11. PMID: 28285324.


5: Hussain RM, Gregori NZ, Ciulla TA, Lam BL. Pharmacotherapy of retinal disease with visual cycle modulators. Expert Opin Pharmacother. 2018 Apr;19(5):471-481. doi: 10.1080/14656566.2018.1448060. Epub 2018 Mar 15. PMID: 29542350.


6: Du M, Phelps E, Balangue MJ, Dockins A, Moiseyev G, Shin Y, Kane S, Otalora L, Ma JX, Farjo R, Farjo KM. Transgenic Mice Over-Expressing RBP4 Have RBP4-Dependent and Light-Independent Retinal Degeneration. Invest Ophthalmol Vis Sci. 2017 Aug 1;58(10):4375–4383. doi: 10.1167/iovs.17-22107. Erratum in: Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4799. PMID: 28813718; PMCID: PMC5560100.


7: Zajc CU, Dobersberger M, Schaffner I, Mlynek G, Pühringer D, Salzer B, Djinović-Carugo K, Steinberger P, De Sousa Linhares A, Yang NJ, Obinger C, Holter W, Traxlmayr MW, Lehner M. A conformation-specific ON-switch for controlling CAR T cells with an orally available drug. Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14926-14935. doi: 10.1073/pnas.1911154117. Epub 2020 Jun 17. PMID: 32554495; PMCID: PMC7334647.


8: Motani A, Wang Z, Conn M, Siegler K, Zhang Y, Liu Q, Johnstone S, Xu H, Thibault S, Wang Y, Fan P, Connors R, Le H, Xu G, Walker N, Shan B, Coward P. Identification and characterization of a non-retinoid ligand for retinol-binding protein 4 which lowers serum retinol-binding protein 4 levels in vivo. J Biol Chem. 2009 Mar 20;284(12):7673-80. doi: 10.1074/jbc.M809654200. Epub 2009 Jan 15. PMID: 19147488; PMCID: PMC2658061.


9: Wang Y, Connors R, Fan P, Wang X, Wang Z, Liu J, Kayser F, Medina JC, Johnstone S, Xu H, Thibault S, Walker N, Conn M, Zhang Y, Liu Q, Grillo MP, Motani A, Coward P, Wang Z. Structure-assisted discovery of the first non- retinoid ligands for Retinol-Binding Protein 4. Bioorg Med Chem Lett. 2014 Jul 1;24(13):2885-91. doi: 10.1016/j.bmcl.2014.04.089. Epub 2014 May 2. PMID: 24835984.


10: Miller R, Sanchez-Kazi C. Recurrent urinary tract infection and nephrocalcinosis: Answers. Pediatr Nephrol. 2021 Mar;36(3):553-554. doi: 10.1007/s00467-020-04650-z. Epub 2020 Jun 23. PMID: 32577805.


11: Miller R, Sanchez-Kazi C. Recurrent urinary tract infection and nephrocalcinosis: Questions. Pediatr Nephrol. 2021 Mar;36(3):551-552. doi: 10.1007/s00467-020-04643-y. Epub 2020 Jun 23. PMID: 32577806.


12: Poliakov E, Samuel W, Duncan T, Gutierrez DB, Mata NL, Redmond TM. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1. PLoS One. 2017 Apr 27;12(4):e0176487. doi: 10.1371/journal.pone.0176487. PMID: 28448568; PMCID: PMC5407626.


13: Cioffi CL, Dobri N, Freeman EE, Conlon MP, Chen P, Stafford DG, Schwarz DM, Golden KC, Zhu L, Kitchen DB, Barnes KD, Racz B, Qin Q, Michelotti E, Cywin CL, Martin WH, Pearson PG, Johnson G, Petrukhin K. Design, synthesis, and evaluation of nonretinoid retinol binding protein 4 antagonists for the potential treatment of atrophic age-related macular degeneration and Stargardt disease. J Med Chem. 2014 Sep 25;57(18):7731-57. doi: 10.1021/jm5010013. Epub 2014 Sep 11. PMID: 25210858; PMCID: PMC4174998.


14: Hassler D, Braun R, Kimmig P. Impfungen. Meningokokken [Vaccinations. Meningococci]. Dtsch Med Wochenschr. 2001 Dec 7;126(49):A1120. German. PMID: 11791518.


15: Safi TS, Munday JN. Improving photovoltaic performance through radiative cooling in both terrestrial and extraterrestrial environments. Opt Express. 2015 Sep 21;23(19):A1120-8. doi: 10.1364/OE.23.0A1120. PMID: 26406742.


16: Badaut J, Bix GJ. Vascular neural network phenotypic transformation after traumatic injury: potential role in long-term sequelae. Transl Stroke Res. 2014 Jun;5(3):394-406. doi: 10.1007/s12975-013-0304-z. Epub 2013 Nov 29. PMID: 24323723; PMCID: PMC4028405.


17: Petrukhin K. Pharmacological inhibition of lipofuscin accumulation in the retina as a therapeutic strategy for dry AMD treatment. Drug Discov Today Ther Strateg. 2013;10(1):e11-e20. doi: 10.1016/j.ddstr.2013.05.004. PMID: 25152755; PMCID: PMC4140438.


18: Aaen GS, Holshouser BA, Sheridan C, Colbert C, McKenney M, Kido D, Ashwal S. Magnetic resonance spectroscopy predicts outcomes for children with nonaccidental trauma. Pediatrics. 2010 Feb;125(2):295-303. doi: 10.1542/peds.2008-3312. PMID: 20123781.


19: Badaut J, Copin JC, Fukuda AM, Gasche Y, Schaller K, da Silva RF. Increase of arginase activity in old apolipoprotein-E deficient mice under Western diet associated with changes in neurovascular unit. J Neuroinflammation. 2012 Jun 18;9:132. doi: 10.1186/1742-2094-9-132. PMID: 22709928; PMCID: PMC3419627.


20: Suder A, Ang JE, Kyle F, Harris D, Rudman S, Kristeleit R, Solca F, Uttenreuther-Fischer M, Pemberton K, Pelling K, Schnell D, de Bono J, Spicer J. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer. 2015 Nov;51(16):2275-84. doi: 10.1016/j.ejca.2015.07.041. Epub 2015 Aug 18. PMID: 26296295.